Please ensure Javascript is enabled for purposes of website accessibility

Is Zomedica a Buy?

By Zhiyuan Sun - Mar 30, 2021 at 6:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This company is going all in on its innovative pet diagnostic machine. Should you go all in on its stock?

Zomedica Pharmaceuticals (ZOM 10.58%) has been one of the most intriguing (and best-performing) healthcare penny stocks in the past year. In fact, an investment of $10,000 in its shares last March would be worth well over $85,000 today. What's behind such astonishing gains? 

As it turns out, the company has built a device that detects hormonal disorders in pets. If that doesn't sound exciting at all, well, investors think otherwise. Zomedica is now a billion-dollar company by market cap. Are shares on a path to take investors to the promised land? Or is the opportunity to make money on Zomedica stock largely over?

Pet satisfied after getting a vet exam.

Image source: Getty Images.

What's with the hype? 

With no product revenue, an annual loss of $16.9 million, and roughly $90 million in assets, Zomedica is clearly still in the very early stages of commercialization of Truforma, a device that measures cortisol levels in dogs and cats via bulk acoustic wave detection technology. But analyzing a company isn't just about looking at its financials. A firm's intangible assets, especially if newly developed, have the potential to generate cash flows in the future, and that's what we need to look at.

This quarter, the company signed an agreement with Miller Vet Supply, the oldest veterinary distributor in the country, and it sold its first device in March. The chief operating officer of Miller Vet said that Truforma is "an industry-changing" technology.

There are 70 issued and pending patents for Truforma. The beauty of the product is that it allows for adrenal and thyroid testing on the spot at a veterinary clinic, so vets don't have to wait for lab results. Truforma is slightly smaller than a desktop printer.

Despite being heavy and costing up to $18,500 per device, immunoassay systems on the market have their own unique advantages. They can detect everything from cardiac abnormalities, endocrine disorders, and chronic diseases to tumor markers, for starters. What's more, the vast majority of the global $3.7 billion pet diagnostic market consists of screening for hereditary diseases and polymerase chain reaction (PCR) testing for tumors. Hence, unless Zomedica can expand its device into testing for these conditions as well, Trufoma won't be a true replacement for the industry standards.

Even though the company is fully funded until 2023 and expects to turn a profit by then, nothing is stopping it from taking advantage of its high stock price. Indeed, over the past year, its share count has increased from roughly 100 million to 972.02 million.

What's the verdict? 

At this point, I'm not convinced that a single pet diagnostic device that can operate in a limited fraction of the testing industry should have a market cap north of $1.6 billion. Investors should know that it's best to consolidate the gains and take profits after such a spectacular run-up. I would definitely wait for the commercialization results to roll in before placing too much faith in Truforma and, in turn, Zomedica stock. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zomedica Pharmaceuticals Corp. Stock Quote
Zomedica Pharmaceuticals Corp.
$0.24 (10.58%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.